Tag Archives: Cancer

Excess Cancer Death Predicted as Treatment Interrupted by COVID-19 | Instant News


Editor’s note: Find the latest COVID-19 news and guides in Medscape Coronavirus Resource Center.

The majority of patients who have cancer or are suspected of having cancer do not access health services in the United Kingdom or the United States because of the COVID-19 pandemic, the first report of an estimated species.

As a result, there will be an excess of deaths among patients suffering from cancer and some comorbidities in both countries during the current coronavirus emergency, the report warns.

The authors calculated that there would be 6270 excess deaths among cancer patients 1 year from now in the UK and 33,890 deaths among cancer patients in the United States. (In the United States, estimates of the number of excess deaths only apply to patients older than 40 years, they note.)

“The underlying underlying cause of this excess death may be due to cancer, COVID-19 or comorbidities (such as myocardial infarction),” Alvina Lai, PhD, University College London, England, and colleagues observed.

“Our data have highlighted how cancer patients with multimorbidity are a very risk group during the current pandemic,” they stressed.

That research was published at ResearchGate as a preprint and has not yet undergone peer review.

Comment on the study of UK Science Media Center, some experts stressed the lack of peer review, noting that this interpretation of data needs to be further refined based on these inputs. One expert suggested that there was “substantial uncertainty that this paper did not communicate enough.” But others argue that this topic is important enough to guarantee the initial release of data.

Chris Bunce, PhD, University of Birmingham, UK, said the research represented “an invaluable contribution.”

“It is universally accepted that early diagnosis and treatment and adherence to treatment regimens save lives,” he said.

“Therefore, the impact related to COVID-19 will cause casualties,” Bunce said.

“And if this information is to influence cancer care and guide policy during the COVID-19 crisis, it is important that the findings are disseminated and discussed immediately, guaranteeing their release in front of the peers’ views,” he added.

In England Medscape comment, oncologist Karol Sikora, MD, PhD, believes that “restarting cancer services cannot come soon.”

“Estimated Numeric Number Estimates”

“It is well known that there have been many changes in the provision of health care for many conditions, including cancer, as a result of all measures to deal with the COVID-19 crisis,” said Kevin McConway, PhD, emeritus professor of applied fields. statistics, Open University, Milton Keynes, United Kingdom.

“It seems inevitable that there will be an increase in deaths in cancer patients if they are infected with a virus or because of changes in the health services available to them, and very possibly also from the socioeconomic effects of the response to the crisis,” he said. continue.

“This study is the first that I have seen that yields a fairly debatable numerical estimate of the number of excess deaths of people with cancer arising from these factors in the United Kingdom and the United States,” he added.

Declining Urgent Reference and the Presence of Chemo

For this study, the team used DATA-CAN, the UK National Center for Health Data Research for Cancer, to assess weekly returns for urgent cancer referrals for early diagnosis and also the presence of chemotherapy for hospitals in Leeds, London and Northern Ireland going back to 2018.

The data reveal that there is a large decrease in the presence of chemotherapy. On average there was a 60% reduction in the prandemic level in eight hospitals in the three regions assessed.

Urgent cancer referrals have fallen by an average of 76% compared to prandemic levels in the three regions.

On the conservative assumption that the COVID-19 pandemic will only affect patients with newly diagnosed cancers (incident cases), the researchers estimate that the proportion of the population affected by an emergency (PAE) is 40% and that the relative impact of an emergency. (RIE) is 1.5.

PAE is a summary measure of exposure to adverse health consequences of emergencies; RIE is a summary measure of the combined impact on infection deaths, changes in health care, physical distance, and economic decline, the authors explain.

Common Comorbidities

“Comorbidity is common in people with cancer,” the study authors wrote. For example, more than a quarter of the study population has at least one comorbidity; more than 14% have two.

For incident cancer, the number of excess deaths continues to increase along with the increase in the number of comorbidities, so that more than 80% of deaths occur in patients with one or more comorbidities.

“When considering the prevalent cancer and the joint incidence with COVID-19 PAE by 40%, we estimate 17,991 excess deaths at RIE 1.5; 78.1% of these deaths occur in patients with comorbidities ≥1,” the authors report.

“The excess risk of death in people living with cancer during COVID-19 emergencies may not only be caused by COVID-19 infection, but also due to unintended health consequences of changes in health service provision, physical or psychological effects from social distance, and economic upheaval, “they declared.

“This is the first study to show recent major changes in the delivery of cancer care at several centers,” the authors observed.

Lai did not disclose relevant financial relationships. Several joint authors have a variety of relationships with industry, as stated in their articles. The commentators did not disclose the relevant financial relationships.

This study is available for download from ResearchGate website.

Follow Medscape Oncology on Twitter for more cancer news: @MedscapeOnc.

.



image source

Popular Clinical Topics: Cancer and COVID-19 | Instant News


Every week, we identify one top search term, speculate about what caused its popularity, and provide infographics on related conditions. If you have thoughts about what is trending and why, please share with us at Indonesia or Facebook.

News about the prevalence of cancer among patients with COVID-19 and the concerns associated with providing cancer care during a pandemic resulted in the topic of this week’s top trending clinical topics. A meta-analysis published in JCO Global Oncology confirm a previous report that suggested that patients with cancer, and survivors, are an important risk population for COVID-19. The new findings are limited by the retrospective nature of the included studies. The study authors hope that additional data from China and Italy will further clarify the types of cancer associated with a higher risk, as well as treatment regimens that increase complications of COVID-19 infection.

Some cancer patients and COVID-19 registrants has been launched recently. Their aim is to determine the characteristics of patients with cancer who have the most severe COVID-19 infection, as well as the estimated severity of the disease, modification and delay of treatment, and clinical outcomes. The American Society of Clinical Oncology (ASCO) requests practice throughout the country to share information about their patients for educational purposes. Information collected through a web-based registry will not be available for commercial purposes. This contradicts data collection conducted by CancerLinQ, a wholly owned subsidiary of ASCO. CancerLinQ has been criticized to enable partner companies to sell access to their data without asking for patient permission.

Patients with cancer that are not infected with COVID-19 are still affected by a pandemic. A survey conducted by the American Cancer Society Cancer Action Network found that almost a quarter (24%) of respondents experienced delays in care or care. Sadder, 12% reported that their treatment was not only postponed, but they also have not been notified when the treatment will be rescheduled. Cancer experts report the difficulties they face in trying to continue to provide the care that their patients need. Many are turning to solutions like telemedicine and other virtual health services. These strategies are among the suggestions given by the author a Special feature articles in Journal of the National Comprehensive Cancer Network . Their list of 10 recommendations includes screening, telemedicine, and restrictive procedures. This article also provides guidelines for the best way to ensure the safety of health workers while providing cancer care during a crisis.

Management of lung cancer during the COVID-19 crisis is a special problem. Experts in Europe issue recommendations intended to minimize the risk of patients infected with SARS-CoV-2 while hospitalized. The author suggests that personalized care must be emphasized. This includes evaluating the possible benefits of treatment and the possibility of delaying surgery. New global registry (TERAVOLT) has been launched to collect data that will be used to develop risk assessment strategies tailored for patients with lung cancer. The author emphasizes that the international consensus on COVID-19 testing in lung cancer is very important to achieve that goal.

The crossover between COVID-19 and cancer is complex and ongoing. When more recommendations and data are available, subjects tend to remain among the top trending clinical topics.



Read more clinical information about COVID-19.

.



image source

Blue Earth Diagnostics CEO Jonathan Allis Appointed as Chair of the UK Rapid Testing Consortium (UK-RTC) for COVID-19 by the UK Department of Health and Social Care | Corona virus | Instant News


OXFORD, UK & BURLINGTON, Mass .– (BUSINESS AREA) – May 1 2020–

Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced that its CEO, Dr Jonathan Allis, has been appointed as Chair of the UK Rapid Testing Consortium (UK-RTC) for COVID-19 by the UK Ministry of Health and Social Care (DHSC). The UK-RTC has been formed to utilize the expertise and resources of the life science industry in the UK in a joint effort to design and develop home use antibody tests to determine whether people have developed antibodies (and possibly, potential immunity) after being contracted and recovered from COVID-19 . It combines knowledge from Oxford University with the skills of developing and manufacturing four British diagnostic companies: Abingdon Health in the UK, BBI Solutions in Wales, Omega Diagnostics in Scotland and CIGA Healthcare in Northern Ireland. In his role as Chair of the UK-RTC, Dr. Allis will act as an independent liaison between participating diagnostic companies and the government. Part time involvement has a limited duration, during which Dr. Allis will maintain his responsibilities as CEO of Blue Earth Diagnostics. The Chair of the UK-RTC is independent from the diagnostic company involved, and Blue Earth Diagnostics is not involved in this initiative.

This press release features multimedia features. See the full release here: https://www.businesswire.com/news/home/20200501005100/en/

Jonathan Allis, CEO of Blue Earth Diagnostics (Photo: Business Wire)

“When DHSC invited me to lead a consortium to develop COVID-19 antibody tests based on new technology developed at Oxford University, and given the urgency of the COVID-19 health crisis worldwide, I felt it was my absolute duty to say ‘yes,'” said Jonathan Allis, D. Phil, CEO of Blue Earth Diagnostics. “Testing for the presence of the SARS-CoV-2 virus (antigen testing) and immune response after COVID-19 (antibody testing) may be done in large hospitals and public and private laboratories now, but what we really need is a home test ( somewhat similar to a home pregnancy test), which can be used to test the entire population. This will help us understand how much of the population is exposed to the virus and help determine plans for people who are returning to work. “

Dr Allis continued, “Medical diagnostics are very important to inform patients of appropriate care and care, and I am honored that my industry experience in the rapid development of health diagnostics might be valuable in this effort.”

“This is a great story about how our manufacturers in the UK are increasing the challenge of COVID-19, and I hope this product will have an impact in our battle against this terrible disease,” said Lord Bethell, Minister of Health for Innovation and Testing. “This is a big step in the right direction. People want to know if they suffer from this disease, with tests they can trust.”

Jonathan Allis is the founder CEO of Blue Earth Diagnostics. Prior to this role, Dr. Allis was General Manager for PET at GE Healthcare Life Sciences, and has global responsibility for GE Healthcare PET agents and PET synthesis business platforms. He previously held positions in R&D, Marketing and Product Development at GE Healthcare, Amersham plc, Siemens Medical Solutions and Oxford Magnet Technology, in the United Kingdom, United States and Germany.

Dr. Allis is the Non-Executive Chair of Polarean Imaging plc and previously served as Chair of the Nuclear Medicine Society and the Molecular Imaging Industry Value Initiative. He has a bachelor’s degree in Physics from the University of Cape Town and a doctorate in Biochemistry from the University of Oxford.

About Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostic company that focuses on developing and commercializing new PET imaging agents to inform clinical management and guide care for cancer patients in the areas of unmet medical needs. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The first product approved and commercially available by the company is Axumin® (fluciclovine F 18), a new molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men with a diagnosis of biochemical recurrence. Fluciclovine F 18 has a wide range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating molecules for other cancers including neuro-oncology. The company’s pipeline includes an innovative innovative Antigen Special Antigen Membrane (PSMA) -added radiohybrid (“rh”) agent, which is a clinical stage, a class of investigation of theranostic compounds, with potential applications in imaging and treatment of prostate cancer. Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A., a global leader in diagnostic imaging. For more information, visit: www.blueearthdiagnostics.com.

View active source version businesswire.com:https://www.businesswire.com/news/home/20200501005100/en/

CONTACT: For Blue Earth Diagnostics (UK)

Clare Gidley

Communication Manager Acting

Tel: +44 (0) 7917 536939

[email protected]

Sam Brown Inc.

Mike Beyer

(M) 1 (312) 961-2502

[email protected] Blue Earth Diagnostics (U.S.)

Priscilla Harlan

Vice President, Corporate Communications

(M) 1 (781) 799-7917

[email protected]

KEY WORDS: MASSACHUSETTS EUROPE UNITED STATES AMERICAN KINGDOM NORTH AMERICA

INDUSTRY KEYWORDS: CLINICAL TRIAL ONCOLOGICAL HEALTH BIOTECHNOLOGY

SOURCE: Blue Earth Diagnostics

Copyright Business Wire 2020.

PUB: 01/05/2020 04:00 AM / DISC: 01/05/2020 04:00 AM

http://www.businesswire.com/news/home/20200501005100/en

Copyright Business Wire 2020.

.



image source

The COVID-19 pandemic will cause additional cancer deaths | Instant News


The COVID-19 pandemic is far from over, the World Health Organization said. At a press conference in Geneva, Switzerland, Monday, Director General, Dr. Tedros Ghebreyesus, said this.

“We continue to urge countries to find, isolate, test and handle all cases and track every contact to ensure this downward trend continues. But the pandemic is far from over. The DKR continues to worry about the rising trend in Africa, Eastern Europe, Latin America and some Asian countries “, he said.

With more than 3.25 million people infected, the health care system of even the most developed countries is overwhelmed. Cancer patients and survivors, for example, are very vulnerable during this epidemic and not only because of the increasing state of their susceptibility to the immune system, which makes them vulnerable to infection. They also risk losing essential cancer care because of the unavailability of resources.

Coronavirus (blue) is biologically simple, but complicated in how it infects hosts. CDC / Hannah A Bullock; Azaibi Tamin

18,000 cancer patients

A new study It has been shown that 18,000 additional cancer patients in the UK will lose their lives during the COVID-19 pandemic mainly because hospitals that treat these patients have to delay and postpone treatment because they are from NHS care. According to chief UK medical advisor Prof. Chris Witty, this is one of the “indirect” costs of a coronavirus pandemic.

Lateness

This new study from University College London (UCL), in collaboration with Data-Can, was one of the first to look at the impact of delays in cancer care provided by the NHS during this pandemic situation. Data-Can is a health data research laboratory that records cancer diagnoses and treatment data from patients throughout the UK.

This study looks at the potential impact of delaying diagnostic tests, screening tests, surgery, and chemo and radiation therapy by the NHS. Also taken into account is the patient’s fear of infection from visiting health facilities. This database includes more than 3.5 million patients in the UK, and from there, results have been obtained.

What was found?

The researchers note that there will be 17,915 additional deaths from cancer and indirectly due to pandemics during this time. Some deaths can be caused by late diagnosis or delayed treatment for cancer.

They note that 6,270 people in the UK, newly diagnosed with cancer, are expected to lose their lives over the next 12 months due to suspension, delays and disruption of their treatment schedule. An additional 17,915 deaths are a 20 percent increase from 89,576 deaths seen each year from cancer in the UK, the report said.

The study also showed that there were 21,678 deaths due to coronavirus infection, and more than 4,300 people had died in care homes over the past two weeks. The NHS has called for continuing care given to seriously ill patients and cancer patients. However, over the past few months since February, cancer referral tests from general practitioners have fallen 76 percent, and there has been a 60 percent decrease in appointments for chemotherapy sessions. However, the NHS has repeatedly urged cancer treatments to “remain unaffected.”

Conclusions and impact

The researchers concluded, “Our data have highlighted how cancer patients with multimorbidity are a very risky group during the current pandemic. To ensure an effective cancer policy and avoid excessive death, both during and after an emergency COVID-19, it is very important to ensure the reporting of specific excess mortality that almost happens in real time, urgent cancer referrals, and treatment statistics, so as to inform the delivery of the most optimal care in this very vulnerable group of patients. “

This study shows that there is a widespread impact of this pandemic that is not only related to coronavirus infection. Cancer Support Macmillan calls this the “forgotten C” of the corona pandemic crisis and has expressed concern over the findings of this study. The study concludes that 80 percent of additional deaths at this time will be caused by newly detected cancers among those who already have other diseases such as high blood pressure, heart disease, diabetes, or obesity.

Dr. Alvina Lal, lead author of the study, a lecturer in health data analysis at the UCL health information institute, said in a statement, “Our findings indicate serious potential for unintended consequences of responses to the Covid-19 pandemic, which could have a negative impact on patients with cancer and other underlying health conditions. “He added that the NHS needs to identify patients who have cancer and are vulnerable at this critical time. Their care must be prioritized so that risks to their health are reduced, he said.

Mark Lawler, lead author of Queen’s University Belfast and Data-Can, said, “The results are alarming. We believe countries need to understand how emergencies affect cancer outcomes quickly, otherwise we risk adding to cancer and other basic health.” conditions with increasing numbers of Covid-19 pandemic deaths. “

Expert

NHS England is spreading awareness among the general public to report and ask for help if there are alarming symptoms or serious health problems. They have asked people to call 999 or visit A&E or GP without delay. The NHS hopes that cancer-related operations will resume soon and hopes to cover the savings suffered during the past few months because patients delay hospital visits and operations.

Peter Johnson, an oncologist from NHS England, also said there were serious implications of late diagnosis and treatment of cancer. He urged people to get a suspicious lump or mole as soon as possible. He said there were “COVID-free cancer centers” in 19 regions in the UK, and this service could be used for cancer diagnosis and treatment.

Harry Hemingway, senior author of the paper and director of the UCL health information institute, said in a statement, “The overall impact of the Covid-19 emergency on death in cancer patients can be enormous. There are many factors operating here, including rapid changes in diagnosis and protocols. care, social distance measures, changes in people’s behavior in seeking medical attention, and [the] the economic impact of Covid-19, and death due to Covid-19 infection. “

Lynda Thomas, Macmillan’s chief executive, added, “This study shows the possibility of direct damage and guarantees caused by coronaviruses on the health of our nation and the lives of people living with conditions such as cancer. newly diagnosed with cancer, we call on all governments to stop cancer from being forgotten C and immediately ensure that cancer services get everything they need to recover and pursue as quickly as possible from a pandemic disorder, which means having the right staff, protective equipment, and testing to provide safe care. “

NHS UK chief executive Simon Stevens has called on the general public to seek health care when needed, and Health Secretary Matt Hancock also announced this week that health services will be normalized and restored as soon as possible.

Journal reference:

.



image source

Retired nurses ‘do not meet the criteria’ to fly to Australia to care for dying sisters, the department said | Instant News


Gail Baker’s dying wish was for his sister to leave New Zealand to take care of him at home towards the end of his life.

But the 65-year-old faces the possibility of dying in hospital without his sister, retired nurse Christine Archer, by her side after the Department of the Interior has rejected four applications for the release of COVID-19 travel on compassion.

“[The Australian Government] won’t let me go, it’s quite disappointing. “

The latest response from the department said Ms. Archer did not “meet the criteria” for release, according to an email between her and the department given to ABC.

“I understand this may be difficult to accept, but further claims under these circumstances will not result in your request for release being reconsidered,” an email from the department dated April 22 read.

The Ministry of Home Affairs has the authority to grant exceptions to “those who have strong and loving reasons to travel to Australia immediately”.

Rejection has compounded Baker’s troubles since the sudden diagnosis of advanced ovarian cancer on March 10.

“I’m not saying I’m more special than poor old people in nursing homes where they haven’t seen their families for weeks.”

The mission is to fulfill the wishes of the dying mother

Cancer retired nurses and midwives were discovered during a doctor’s visit after falling at his home in Bowraville on NSW Mid North Coast.

Gail Baker still hopes that her sister, a retired nurse, will be able to travel from New Zealand to care for her in her final months.(Provided)

He spent time at Coffs Harbor Hospital where the doctor issued a grim prognosis that he had weeks or months to live.

Ms. Archer was on the Vasco da Gama cruise back to New Zealand when she got a call about her sister’s cancer.

He tried to get off at a stop in Western Australia and retire there for two weeks before traveling to help Ms. Baker, but her request was refused.

Gail Baker and Christine Archer
Gail (left) and Christine (right) last met each other in Sydney six years ago.(Provided)

Ms. Archer has since completed her mandatory self-isolation in New Zealand and has worked tirelessly to be with her sister.

Back in Australia, Ms. Baker’s only daughter, Erica Peterson, has regularly traveled hundreds of kilometers between her home in Uralla in the New England region to help her mother in the Bellingen palliative care unit.

While Ms. Baker is at home for now, Ms. Peterson said it was uncertain how long she would be able to stay there.

Peterson said it was very important his aunt came to Australia because the mother of three children would not be able to pay all the time so that her mother could see her days at home.

“I am somewhat divided between caring for Mum and caring for my children,” Peterson said.

‘There is no mercy from the Government’

After her first three applications, Ms. Archer was asked to provide further supporting documentation, which she did in the fourth application on April 22.

In her latest application to the Department of the Interior, Ms. Archer provided a letter from the health authority describing the condition of her sister, as well as a birth certificate, receipt of a flexible return ticket, and Ms. Archer’s nursing qualifications.

But it was rejected again, and Ms. Peterson said she could not understand why.

He said that his mother’s mind was rejected by her dying wish, surrounded by her grandchildren, sisters and family, very heartbreaking and cruel.

“Mum is a positive person in many people’s lives,” he said.

“Seeing him being treated like this without mercy from the Government is not right at all.”

Gail Baker with her granddaughter.
Gail Baker with her granddaughter.(Provided: Erica Peterson)

Ms. Peterson and her husband, Matt, also asked federal members for Cowper, Pat Conaghan, for help.

In a statement, Conaghan said he had referred the matter to the parliament’s liaison office for internal affairs.

“While I sympathize with my family, travel restrictions are imposed under the guidance of the Chief of Medical Staff to stop the spread of the corona virus to Australia and help save lives,” Conaghan said.

A desperate plea

Ms. Archer has pinned her hopes on the fifth travel exemption application.

“I tried to be optimistic, but it was difficult to be rejected many times,” he said.

The family is also optimistic about talks between the Governments of Australia and New Zealand to lift travel bans between the two countries.

When he used his time at home in Bowraville, Ms. Baker still hoped her sister could take care of her like the couple did when their mother died.

“It’s a very beautiful thing for Mum to be able to do before she dies. I want to think that I can do the same thing,” Ms Baker said.

Meanwhile, Ms. Archer has a strong message for the Federal Government.

The Department of the Interior has been contacted for comment.

Space to play or pause, M to mute, left and right arrows to search, up and down arrows for volume.

What are the long-term costs to access early retirement funds?

.



image source